Crucell, Novartis to evaluate antibodies using STAR technology

By Lisa Kerner

Charlotte, N.C., Sept. 14 - Crucell NV will apply its STAR technology to different monoclonal antibodies for the selection of biopharmaceutical production cell lines in an evaluation program with Novartis AG.

Additional details were not disclosed.

Crucell is a biotechnology company based in Leiden, the Netherlands.

Novartis is a pharmaceutical company based in Basel, Switzerland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.